Sign in

Colin Kosse

Research Analyst at Baird Financial Group, Inc.

Colin Kosse is an Equity Research Analyst at Robert W. Baird & Co., specializing in company and sector analysis within the financial services industry. He provides research coverage on specific public companies, delivering data-driven performance insights for institutional clients; however, detailed public metrics on his investment performance, company coverage list, and analyst ranking information are not presently available. Beginning his career as a financial analyst, Kosse has built expertise in equity research and currently leverages his analytical background at Robert W. Baird & Co.; previous employer and career timeline details are not published in available public records. He maintains professional credentials required for securities analysis, likely including FINRA Series 7 and Series 63 or 65 licenses, reflecting industry compliance.

Colin Kosse's questions to Apellis Pharmaceuticals (APLS) leadership

Question · Q1 2025

Colin Kosse asked about the perceived risk of the third-party co-pay assistance programs not being refunded and potentially going away completely.

Answer

Executive David Acheson responded that the situation is unpredictable. He stated that Apellis is operating under the assumption that the funding will not return. Consequently, the company anticipates sample usage will remain elevated, and its strategy is focused on managing the balance between sample and commercial doses.

Ask follow-up questions

Fintool

Fintool can predict Apellis Pharmaceuticals logo APLS's earnings beat/miss a week before the call

Let Fintool AI Agent track Colin Kosse for you

Get briefed when they ask questions on calls

Best AI Agent for Equity Research

Performance on expert-authored financial analysis tasks

Fintool-v490%
Claude Sonnet 4.555.3%
o348.3%
GPT 546.9%
Grok 440.3%
Qwen 3 Max32.7%

Try Fintool for free